Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects.

Objective: Somatostatin not only inhibits basal and GHRH-stimulated GH secretion but might also enhance pituitary GH responsivity to GHRH under different temporal conditions. We investigated whether octreotide, a long-acting somatostatin analogue, has any positive actions on GHRH-induced GH release in normal human subjects.
Design: The study consisted of three protocols. At 0800 hours, after fasting overnight, all subjects received 1 microgram/kg GHRH i.v. bolus at 0 minutes. In each protocol, either octreotide (200 micrograms s.c.) or placebo were given respectively 8, 12, or 16 hours prior to GHRH challenge.
Subjects: Three groups of eight normal volunteers (four female and four male in each group), aged 18-35 years, were randomly assigned to each protocol.
Measurements: Growth hormone was measured by IRMA. Samples for GH assay were taken at -30 and 0 minutes and then at 15-minute intervals up to 120 minutes.
Results: When placebo or octreotide were administered 8 hours before GHRH, peak GH levels were respectively (mean +/- SE, mU/l) 56.2 +/- 16.6 and 60.8 +/- 11.4 (NS). Also, when placebo or the somatostatin analogue were administered 16 hours prior to GHRH, peak GH levels were comparable (61.0 +/- 7.4 vs 58.8 +/- 7.4, NS). However, in the group receiving placebo or octreotide 12 hours prior to GHRH, the GH responses to GHRH were clearly enhanced by octreotide administration (peak GH levels, mU/l, 55.6 +/- 21.6 vs 104.0 +/- 17.4, P < 0.02). This enhancement of GH responses was observed in all subjects.
Conclusions: Octreotide administration did not affect GH responses to GHRH when given either 8 or 16 hours prior to GHRH. However, octreotide enhanced GHRH-induced GH release when administered 12 hours prior to GHRH. It thus appears that, under particular temporal conditions, octreotide may act positively on GH secretion in man.